| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 01/22/2004 | WO2003055462A3 Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof |
| 01/22/2004 | WO2003055447A3 Heterocyclic acridone inhibitors of impdh enzyme |
| 01/22/2004 | WO2002078643A3 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 01/22/2004 | WO2002069886A3 Modified proteins, designer toxins, and methods of making thereof |
| 01/22/2004 | US20040014798 Skin disorders; hormone replacement therapy |
| 01/22/2004 | US20040014796 Antiinflammatory agents; rheumatic diseases; antitumor agents |
| 01/22/2004 | US20040014788 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht receptor agonists |
| 01/22/2004 | US20040014787 Hormone inhibitors; controlling fertility |
| 01/22/2004 | US20040014783 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 01/22/2004 | US20040014778 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 01/22/2004 | US20040014751 Antidiabetic agents |
| 01/22/2004 | US20040014748 Cardiovascular disorders, central nervous susyem disorders |
| 01/22/2004 | US20040014743 Mbreast and prostate anticancer agents; viricides; alopecia |
| 01/22/2004 | US20040014723 Calcilytic compounds |
| 01/22/2004 | US20040014685 Compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/22/2004 | US20040014634 Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals |
| 01/22/2004 | US20040014089 Culturing a transformant in a medium, allowing the polypeptide having phospholipase a2 activity fo form and accumulating in the culture, recovering the polypeptide thus formed |
| 01/22/2004 | US20040013747 An anaesthetic mixture comprising a drug, acids, a metal nitrite; a membrane is used to prevent direct contact of the skin while diffusing the active drug and nitric oxide vasodilator; topical application |
| 01/22/2004 | US20040013727 Hydrophilic gel foaming matrix; cellulose ethers |
| 01/22/2004 | US20040013725 Storage stable thyroxine active drug formulations and methods for their production |
| 01/22/2004 | US20040013676 Administering dosage of mature dendritic cells in carrier |
| 01/22/2004 | US20040013645 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 01/22/2004 | US20040013637 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 01/22/2004 | DE10230381A1 Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen Use of inhibitors of alanyl-aminopeptidase, and pharmaceutical preparations comprising them |
| 01/22/2004 | CA2492561A1 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | CA2492046A1 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 01/22/2004 | CA2490818A1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/21/2004 | EP1382616A2 Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor |
| 01/21/2004 | EP1382605A2 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands |
| 01/21/2004 | EP1382597A2 Steroid receptor modulator compounds and methods |
| 01/21/2004 | EP1382350A1 Preventives for postoperative recurrence of premenopausal breast cancer |
| 01/21/2004 | EP1382340A1 Therapeutic uses of dehydroepiandrosterone for treating diminished libido and osteoporosis |
| 01/21/2004 | EP1382337A1 Novel formulation containing paroxetine |
| 01/21/2004 | EP1381686A2 Inactivation of genes of the mep pathway |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381608A1 Cyclohexylphenyl vasopressin agonists |
| 01/21/2004 | EP1381607A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepine-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists |
| 01/21/2004 | EP1381602A1 Heterocyclyldicarbamides as caspase inhibitors |
| 01/21/2004 | EP1381431A1 Aromatase inhibition to enhance assisted reproduction |
| 01/21/2004 | EP1381371A2 Hormone replacement therapy |
| 01/21/2004 | EP1381370A1 N-biphenylcarbonyl- and n-phenylpyridylcarbonyl substituted bi- and tricyclic azepines and diazepines as vasopressing agonists |
| 01/21/2004 | EP1381357A2 Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity |
| 01/21/2004 | EP1242415B1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 01/21/2004 | EP1131083B1 Use of growth hormone releasing compounds and their antagonists for the treatment of tumors |
| 01/21/2004 | CN1469875A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469874A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469873A Piperidine compounds as anti-allergic |
| 01/21/2004 | CN1469871A Substituted dipeptides as growth hormone secretagogues |
| 01/21/2004 | CN1469743A 雌激素受体调节剂 Estrogen receptor modulators |
| 01/21/2004 | CN1469734A Pharmaceutical form of administration for peptides, method for its production and use |
| 01/21/2004 | CN1468863A Polyglycol-human growth hormone conjugate and its prepn process and medicinal use |
| 01/20/2004 | US6680328 Cholinergic ligands of nicotinic acetyl choline receptors for treatment of central nervous system disorders, smooth muscle contraction disorders, endocrine diseases/disorders, neurodegeneration, inflammation, pain, and drug withdrawal |
| 01/20/2004 | US6680327 Crystalline form VII of cabergoline |
| 01/15/2004 | WO2004005881A2 Methods for identification of compounds modulating insulin resistance |
| 01/15/2004 | WO2004005314A1 ESTRIENO[3,2-b]/[3,4-c]PYRROLE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS |
| 01/15/2004 | WO2004005310A2 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/15/2004 | WO2004005299A1 Polymorphic forms of a 4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivative |
| 01/15/2004 | WO2004005249A1 Pyrrolidine derivatives as oxytocin antagonists |
| 01/15/2004 | WO2004005229A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | WO2004004781A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 01/15/2004 | WO2004004780A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | WO2004004779A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | WO2004004750A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | WO2004004729A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | WO2004004703A1 m-PHENYLENEDIAMINE DERIVATIVE |
| 01/15/2004 | WO2004004638A2 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects |
| 01/15/2004 | WO2004004634A2 Infertility treatment with exemestane |
| 01/15/2004 | WO2003094831A3 Novel diazabicyclic biaryl derivatives |
| 01/15/2004 | WO2003089434A3 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| 01/15/2004 | WO2003080118A3 Combination of an aldosterone receptor antagonist and a fibric acid derivative |
| 01/15/2004 | WO2003060130A3 Pim-3 kinase as a target for type 2 diabetes mellitus |
| 01/15/2004 | WO2003055992A3 A method for the establishment of a pluripotent human blastocyst-derived stem cell line |
| 01/15/2004 | US20040010148 Antiinflammatory agents, antiallergens, antiproliferative agents, immunosuppressants, antidiabetic agents, cardiovascular disorders |
| 01/15/2004 | US20040010142 Potassium channel moderators; antidiabetic agents |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010020 Trifluoromethyl-substituted nitrogen compounds; treating type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma |
| 01/15/2004 | US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade |
| 01/15/2004 | US20040009984 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure |
| 01/15/2004 | US20040009980 Calcilytic compounds |
| 01/15/2004 | US20040009912 Method for treating schizoprhenia and related phychoes, and the use of erythropoietin or erythropoietin derivatives for treating schizophrenic disorders and related pyschoes |
| 01/15/2004 | US20040009595 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 01/15/2004 | US20040009231 hGH (human growth hormone) formulations for pulmonary administration |
| 01/15/2004 | DE10226326A1 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene 9-alpha-substiuierte estratrienes as selective estrogens effective |
| 01/15/2004 | CA2491994A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol |
| 01/15/2004 | CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | CA2491445A1 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects |
| 01/15/2004 | CA2491372A1 Infertility treatment with exemestane |
| 01/15/2004 | CA2491132A1 Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2489402A1 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/15/2004 | CA2489396A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | CA2487856A1 Methods for identification of compounds modulating insulin resistance |
| 01/14/2004 | EP1380582A1 FSH mimetics for the treatment of infertility |
| 01/14/2004 | EP1380301A1 Pharmaceutical combination of ethinylestradiol and dropirenone for use as a contraceptive |
| 01/14/2004 | EP1380300A1 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent |
| 01/14/2004 | EP1380296A1 Hsp inductor |
| 01/14/2004 | EP1379876A2 Novel method for screening inhibitors of the linkage between the neuronal nitric oxide synthase associated protein and the protein inhibiting neuronal nitric oxide synthase |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |